ARTEMIS: Ravulizumab to Protect Patients with CKD from CSA-AKI and MAKE - ARTEMIS

Exclusion Criteria

• - Emergency or salvage cardiac surgery is expected at screening or randomization, as assessed by the Investigator.
• - Single-vessel CABG without valve surgery is planned.
• - Off-pump surgery is planned (eg, surgery without CPB).
• - Recipient of a solid organ or bone marrow transplantation.
• - Cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump, extracorporeal membrane oxygenation, or left ventricular assist device within 72 hours of randomization.
• - Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.
• - History of unexplained, recurrent infection.
• - Any use of KRT or presence of AKI
• within 30 days of randomization
• - Use of any complement inhibitors, or plasmapheresis or plasma exchange within the year prior to Screening, or planned use during the course of the study.
• - Participant is not willing to be vaccinated against N meningitidis or is unwilling to receive prophylactic treatment with appropriate antibiotics, if needed
• - History of or unresolved N meningitidis infection.